文献速递皮肤肿瘤

局部氟尿嘧啶与咪喹莫特治疗光化性角化病预防角质形成细胞癌的比较效果:队列研究

Comparative effectiveness of treatment of actinic keratosis with topical fluorouracil and imiquimod in the prevention of keratinocyte carcinoma: A cohort study.
PubMed 文献 · J Am Acad Dermatol · 2018-11-17

该队列研究纳入2007年开具5-氟尿嘧啶或咪喹莫特处方的5700例光化性角化病患者,采用意向性治疗分析比较两种治疗预防角质形成细胞癌的效果。结果显示5-氟尿嘧啶与任何角质形成细胞癌风险降低相关(aHR 0.86,95%CI 0.76-0.97),但肿瘤亚型及部位特异性风险无显著差异,2年和5年累积风险差异无统计学意义。

要点

  • 5-氟尿嘧啶较咪喹莫特降低任何角质形成细胞癌风险(aHR 0.86,95%CI 0.76-0.97)。
  • 鳞状细胞癌和基底细胞癌亚型风险无显著差异(aHR分别为0.89和0.87)。
  • 部位特异性角质形成细胞癌风险及2年、5年累积风险无显著差异。

核心结论

  • 在真实实践中,5-氟尿嘧啶在降低总体角质形成细胞癌风险方面较咪喹莫特更有效,但短期或长期部位特异性角质形成细胞癌风险无差异。

研究设计与样本

  • 研究为队列研究,纳入2007年开具5-氟尿嘧啶或咪喹莫特处方治疗光化性角化病的5700例受试者,采用意向性治疗分析并控制潜在混杂变量。

主要发现

  • 5-氟尿嘧啶与任何角质形成细胞癌风险降低相关(aHR 0.86,95%CI 0.76-0.97),而鳞状细胞癌(aHR 0.89,95%CI 0.74-1.07)和基底细胞癌(aHR 0.87,95%CI 0.74-1.03)风险无显著差异。
  • 部位特异性角质形成细胞癌风险无显著差异(aHR 0.96,95%CI 0.81-1.14)。
  • 5-氟尿嘧啶与咪喹莫特组间2年或5年角质形成细胞癌累积风险无显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 对其他实践环境的普遍性可能有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The effectiveness of 5-fluorouracil compared with that of imiquimod for preventing keratinocyte carcinoma is unknown. OBJECTIVE: To compare the effectiveness of 5-fluorouracil and that of imiquimod in preventing keratinocyte carcinoma in a real-world practice setting. METHODS: We identified 5700 subjects who filled prescriptions for 5-fluorouracil or imiquimod for treatment of actinic keratosis in 2007. An intention-to-treat analysis controlling for potential confounding variables was used to calculate 2- and 5-year cumulative risk differences for subsequent keratinocyte carcinoma overall and in field-treated areas. RESULTS: 5-Fluorouracil was associated with a statistically significant decreased risk of any keratinocyte carcinoma compared with imiquimod (adjusted hazard ratio [aHR], 0.86; 95% confidence interval [CI], 0.76-0.97), but there were no significant differences in risk by tumor subtype (for squamous cell carcinoma: aHR, 0.89; 95% CI, 0.74-1.07; for basal cell carcinoma: aHR, 0.87; 95% CI, 0.74-1.03) or site-specific keratinocyte carcinoma (aHR, 0.96; 95% CI, 0.81-1.14). There were no significant differences in 2- or 5-year cumulative risk of keratinocyte carcinoma among those treated with 5-fluorouracil versus with imiquimod. LIMITATIONS: Generalizability to other practice settings may be limited. CONCLUSIONS: Whereas 5-fluorouracil was more effective in reducing keratinocyte carcinoma risk overall, we found no differences in the short- or long-term risk of subsequent site-specific keratinocyte carcinoma in a real-world practice setting.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Neugebauer R, Su KA, Zhu Z, et al. Comparative effectiveness of treatment of actinic keratosis with topical fluorouracil and imiquimod in the prevention of keratinocyte carcinoma: A cohort study. J Am Acad Dermatol. 2018. PMID: 30458208. doi:10.1016/j.jaad.2018.11.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。